Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RVTY
RVTY logo

RVTY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Revvity Inc (RVTY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
105.630
1 Day change
5.74%
52 Week Range
118.300
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Revvity Inc (RVTY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive signals such as recent congressional purchases and a modest price increase, the technical indicators, options sentiment, and analyst ratings suggest a neutral to slightly cautious outlook. The stock is trading near the top of its historical valuation range, and there are no strong proprietary trading signals or news catalysts to justify immediate action.

Technical Analysis

The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 49.278, and moving averages are converging, showing no clear trend. The stock is trading below the pivot point of 101.182, with key support at 97.61 and resistance at 104.754.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The low put-call ratio in open interest suggests a moderately bullish sentiment, but the high option volume put-call ratio (1.6) indicates bearish short-term trading sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
14

Positive Catalysts

  • Congressional trading data shows two recent purchase transactions with a median amount of $4.1M, indicating strong confidence from influential figures. Additionally, Barclays raised its price target to $105, and TD Cowen highlighted improving demand and management confidence.

Neutral/Negative Catalysts

  • Analyst sentiment is mixed, with some firms lowering price targets and expressing concerns about valuation and margin risks. Wolfe Research noted the stock is at the top of its historical valuation range. Technical indicators do not support a strong upward trend, and options data shows bearish short-term sentiment.

Financial Performance

Financial data for the latest quarter is unavailable, making it difficult to assess growth trends or profitability. However, analyst commentary suggests improving Pharma/A&G demand and software strength.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst ratings are mixed, with a combination of Buy, Neutral, and Hold ratings. Price targets range from $90 to $120, with the average leaning towards a cautious outlook. Wolfe Research and Stifel highlight valuation concerns, while TD Cowen and Baird remain optimistic about growth prospects.

Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
Wall Street analysts forecast RVTY stock price to rise
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 105.630
sliders
Low
105
Averages
113.38
High
123
Current: 105.630
sliders
Low
105
Averages
113.38
High
123
Wolfe Research
Peer Perform
initiated
AI Analysis
2026-06-01
Reason
Wolfe Research
Price Target
AI Analysis
2026-06-01
initiated
Peer Perform
Reason
Wolfe Research assumed coverage of Revvity with a Peer Perform rating. The firm notes that while it is "intrigued" by the stock's general valuation and likes the recent portfolio cleanup even if generous approach to accounting, adding however that relative to its history of carrying a discount multiple, it is at top end of a roughly 15-year range, so the stock is "not relatively cheap", the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$95 -> $105
2026-05-07
Reason
Barclays
Price Target
$95 -> $105
2026-05-07
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Revvity to $105 from $95 and keeps an Equal Weight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RVTY
Unlock Now

People Also Watch